Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TPF sequential therapy versus cisplatin-based chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
2006-007076-15Phase 3Active
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cisplatin, fluorouracil and carboplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: 3-year overall survival. Started Jul 2009; status: active.
02
Drugs
docetaxelcisplatinfluorouracilcarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-007076-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007076-15.